A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma

被引：1

作者：

Gurumurthi, Ashwath ^{[1
]}

Bantilan, Kurt S. ^{[1
]}

Hamlin, Paul A. ^{[1
]}

Kumar, Anita ^{[1
]}

Matasar, Matthew ^{[1
,2
]}

Zhu, Menglei ^{[3
]}

Joseph, Ashlee ^{[1
]}

Castro, Ali ^{[1
]}

Biggar, Erin ^{[1
]}

Salles, Gilles ^{[1
]}

Zelenetz, Andrew D. ^{[1
]}

von Keudell, Gottfried ^{[1
,4
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY 10065 USA

[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[3] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA

[4] Beth Israel Deaconess Canc Ctr, Dept Pathol, Boston, MA USA

来源：

LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 14期

关键词：

HISTONE DEACETYLASE INHIBITOR; NON-HODGKIN-LYMPHOMA; CRITERIA;

D O I：

10.1080/10428194.2024.2398658

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2224 / 2227

页数：4

共 14 条

[1] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[2] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification [J].

Cheson, Bruce D. ;

Fisher, Richard I. ;

Barrington, Sally F. ;

Cavalli, Franco ;

Schwartz, Lawrence H. ;

Zucca, Emanuele ;

Lister, T. Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :3059-+

[3] A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma [J].

Evens, Andrew M. ;

Balasubramanian, Sriram ;

Vose, Julie M. ;

Harb, Wael ;

Gordon, Leo I. ;

Langdon, Robert ;

Sprague, Julian ;

Sirisawad, Mint ;

Mani, Chitra ;

Yue, Jeanne ;

Luan, Ying ;

Horton, Sharon ;

Graef, Thorsten ;

Bartlett, Nancy L. .

CLINICAL CANCER RESEARCH, 2016, 22 (05) :1059-1066

[4] Therapeutic options for relapsed/refractory mantle cell lymphoma [J].

Eyre, Toby A. ;

Cheah, Chan Y. ;

Wang, Michael L. .

BLOOD, 2022, 139 (05) :666-677

[5] The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line [J].

Hagiwara, Kazumi ;

Kunishima, Shinji ;

Iida, Hiroatsu ;

Miyata, Yasuhiko ;

Naoe, Tomoki ;

Nagai, Hirokazu .

APOPTOSIS, 2015, 20 (07) :975-985

[6] A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naive, TP53-Mutant Mantle Cell Lymphoma [J].

Kumar, Anita ;

Soumerai, Jacob ;

Abramson, Jeremy S. ;

Barnes, Jeffrey A. ;

Caron, Philip ;

Chabowska, Maria ;

Devlin, Mary ;

Dogan, Ahmet ;

Falchi, Lorenzo ;

Garcia, Rayna N. ;

Grieve, Clare ;

Haskell, Emma ;

Haydu, Julie E. ;

Johnson, Patrick Connor ;

Joseph, Ashlee ;

Kelly, Hailey E. ;

Labarre, Alyssa ;

Littlejohn, Emerald D. ;

Lue, Jennifer Kimberly ;

Mi, Joanna ;

Martignetti, Rosalba ;

McCambridge, Grace ;

Moskowitz, Alison ;

Owens, Colette ;

Plummer, Sean F. ;

Puccio, Madeline G. ;

Salles, Gilles ;

Seshan, Venkatraman ;

Slupe, Natalie ;

Zelenetz, Andrew D. .

BLOOD, 2023, 142

[7] Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations [J].

Mondello, Patrizia ;

Brea, Elliott J. ;

De Stanchina, Elisa ;

Toska, Eneda ;

Chang, Aaron Y. ;

Fennell, Myles ;

Seshan, Venkatraman ;

Garippa, Ralph ;

Scheinberg, David A. ;

Baselga, Jose ;

Wendel, Hans-Guido ;

Younes, Anas .

JCI INSIGHT, 2017, 2 (06)

[8] Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study [J].

Ribrag, Vincent ;

Kim, Won Seog ;

Bouabdallah, Reda ;

Lim, Soon Thye ;

Coiffier, Bertrand ;

Illes, Arpad ;

Lemieux, Bernard ;

Dyer, Martin J. S. ;

Offner, Fritz ;

Felloussi, Zakia ;

Kloos, Ioana ;

Luan, Ying ;

Vezan, Remus ;

Graef, Thorsten ;

Morschhauser, Franck .

HAEMATOLOGICA, 2017, 102 (05) :903-909

[9] Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study [J].

Rule, S. ;

Jurczak, W. ;

Jerkeman, M. ;

Rusconi, C. ;

Trneny, M. ;

Offner, F. ;

Caballero, D. ;

Joao, C. ;

Witzens-Harig, M. ;

Hess, G. ;

Bence-Bruckler, I. ;

Cho, S-G ;

Thieblemont, C. ;

Zhou, W. ;

Henninger, T. ;

Goldberg, J. ;

Vermeulen, J. ;

Dreyling, M. .

LEUKEMIA, 2018, 32 (08) :1799-1803

[10] Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma [J].

Saba, Nakhle S. ;

Liu, Delong ;

Herman, Sarah E. M. ;

Underbayev, Chingiz ;

Tian, Xin ;

Behrend, David ;

Weniger, Marc A. ;

Skarzynski, Martin ;

Gyamfi, Jennifer ;

Fontan, Lorena ;

Melnick, Ari ;

Grant, Cliona ;

Roschewski, Mark ;

Navarro, Alba ;

Bea, Silvia ;

Pittaluga, Stefania ;

Dunleavy, Kieron ;

Wilson, Wyndham H. ;

Wiestner, Adrian .

BLOOD, 2016, 128 (01) :82-92

← 1 2 →